Summary
This observational and retrospective cohort study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly oral (PO) dose of 0.2 mg/kg, is an effective pre-exposure prophylaxis (PrEP) method for the spread of Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2), in the healthcare workers.
The study began on June 29, 2020 and ended on July 26, 2020, where 713 active healthcare personnel were included for the analysis, of which 326 adhered to a weekly prophylactic program with Ivermectin for Coronavirus Disease-19 (COVID-19), designed by Grupo Rescue task force, that runs both medical centers, and 387 healthcare personnel who did not adhere to the program were assigned to the control group. A SPSS Propensity Score Matching procedure was applied in a 1:1 ratio to homogeneously evaluate the groups that were made up of 271 participants each. In 28 days of follow-up, a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed 1.8% compared to those who did not take it 6.6%, (p-value = 0.006) and a reduction of the risk of a positive Chain Reaction of Real-Time Polymerase Transcription (RT-PCR) COVID-19 test by 74% (HR 0.26, 95% CI [0.10,0.71]). These results support the use of weekly Ivermectin as a compassionate preventive method in the healthcare personnel.
The protocol of this study is available at Clinicaltrials.gov Identifier: NCT04832945
- SARS-CoV-2
- COVID-19
- coronavirus
- pre-exposure prophylaxis
- PrEP
- healthcare personnel
- healthcare worker
- Ivermectin
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Clinicaltrials.gov Identifier: NCT04832945
Funding Statement
Grupo Rescue National Network of Health Services, in Dominican Republic, was in charge of all the financial support of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Grupo Rescue Ethical Commission at Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The demographic data of the workers, they were extracted from the Sigma software in Centro Medico Punta Cana and an internal development software in Centro Medico Bournigal. The compilation of the information from RT-PCR COVID-19 reports was done by consulting the Referencia Laboratorio Clinico system. The records of both medical centers, were consolidated into a single record by the Head of the Nursing Department, individualizing the worker, date of report and outcome (hospitalization and/or death).
